Z0063

DRUG2 trials

Sponsors

Sanofi

Conditions

Gastroesophageal Reflux Disease

Phase 1

Scintigraphy Study to Compare the Antireflux Activity of the Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects

CompletedNCT03065816

SanofiGastroesophageal Reflux Disease

Start: 2017-02-09End: 2017-05-02Updated: 2022-04-25

PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects

CompletedNCT03069963

SanofiGastroesophageal Reflux Disease

Start: 2017-02-24End: 2017-04-23Updated: 2022-05-12